Clinical trials: Detrusor Overactivity
Urinary Bladder, Overactive, Effect of Drug
Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity
To investigates the effects of combined pharmacotherapy with solifenacin and mirabegron versus solifenacin with vaginal estrogen cream in women with detrusor overactivity.
- Trial name
- NCT06197295
- Testing
- Solifenacin with vaginal estrogen cream, Combination pharmacotherapy
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- Mackay Memorial Hospital
Lower Urinary Tract Symptoms
Filling and Emptying Cystometries ("Backwards Cystometry"): a Feasibility and Validation Study
This study evaluate the feasibility and the accuracy of an emptying cystometry in order to simplify the manometric follow-up of overactive detrusor in neurological patients under anticholinergic or botulinum toxin injections.
- Trial name
- NCT03255421
- Testing
- Pressure measurement
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Pierre and Marie Curie University
Urinary Bladder, Neurogenic
A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition
The objective of the study is to find out if the medicine fesoterodine is a useful treatment in children with bladder muscle overactivity caused by a neurological condition. Children will be aged 6 to 17 years old.
- Trial name
- NCT01557244
- Testing
- Fesoterodine PR 4 mg, Fesoterodine PR 8 mg, Oxybutynin
- Where
- 84 sites in United States, Belgium and 23 more
- Volunteers
- 181 people
- Sponsor
- Pfizer
Overactive Bladder, Bladder Pain Syndrome
Migraine Medication Effects on Urinary Symptoms
A prospective observational cohort trial to study the effects of CGRP inhibitors (CGRPi) on lower urinary tract symptoms (LUTS) and bladder/pelvic pain.
- Conditions
- Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome
- Trial name
- NCT06212661
- Testing
- Ubrogepant, Rimegepant, Atogepant
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- The Cleveland Clinic
Urinary Incontinence, Urinary Bladder, Overactive
Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korea
This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of botulinum toxin Type A to treat urinary incontinence in patients with neurogenic detrusor overactivity (NDO) or overactive bladder…
- Trial name
- NCT02010788
- Testing
- botulinum toxin Type A
- Where
- South Korea
- Volunteers
- 523 people
- Sponsor
- Allergan
Neurogenic Detrusor Overactivity
A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity
People with neurogenic detrusor overactivity (NDO) have poor bladder control because of how their nerves to the bladder are wired. This can cause high pressure in the bladder, causing it to leak urine by accident (incontinence).
- Trial name
- NCT05621616
- Testing
- mirabegron
- Where
- 3 sites in Philippines, Poland
- Volunteers
- 7 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Urinary Incontinence, Overactive Bladder
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2
The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult subjects treated for…
- Trial name
- CONTENT2 (NCT02660359)
- Testing
- Botulinum toxin type A
- Where
- 82 sites in Argentina, Australia and 14 more
- Volunteers
- 258 people
- Sponsor
- Ipsen
Spinal Cord Injury, Neurogenic Detrusor Overactivity
Is the Nerve Growth Factor (NGF) a Useful Biomarker in Neurogenic Bladder Dysfunction After Spinal Cord Injury?
Spinal cord injury (SCI) almost always affects bladder function as well. As a result of this bladder dysfunction, individuals with SCI have to undergo regular invasive examination of their bladder function (urodynamic…
- Conditions
- Spinal Cord Injury, Neurogenic Detrusor Overactivity, Neurogenic Lower Urinary Tract Dysfunction
- Trial name
- NCT02138149
- Where
- Switzerland
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Swiss Paraplegic Research, Nottwil
Mixed Urinary Incontinence, Urinary Incontinence, Stress
Pharmacological vs Surgical Treatment for Mixed Incontinence
In patients with symptoms of mixed incontinence (loss of urine associated with coughing/sneezing/laughing, and loss of urine associated with the strong urge to void), is surgical treatment with tension free vaginal tape or…
- Conditions
- Mixed Urinary Incontinence, Urinary Incontinence, Stress, Urinary Incontinence, Urge
- Trial name
- NCT00523068
- Testing
- Tolterodine, tension free vaginal tape
- Where
- United Kingdom
- Sponsor
- Imperial College London
Overactive Bladder
Topical Oestrogens and Antimuscarinics In The Treatment Of Detrusor Overactivity
Despite the great number of reports about the efficacy of oestrogens or antimuscarinics on OAB symptoms, so far no author has tried to investigate whether the concomitant administration of these two drugs, acting on two different…
- Trial name
- NCT00648310
- Testing
- Tolterodine 4 mg, arm 2: Tolterodine 4 mg + local oestrogens once daily for 12 weeks
- Where
- Italy
- Sponsor
- Università degli Studi dell'Insubria
Detrusor Hyperreflexia
Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition
This study will evaluate the safety and effectiveness of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in children who have a neurological condition (e.g.
- Trial name
- NCT00224016
- Testing
- Oxybutynin
- Where
- 23 sites in United States
- Volunteers
- 57 people
- Sponsor
- Watson Pharmaceuticals
Overactive Bladder
Different Injection Number of the Same Dose of Botulinum Toxin A on Overactive Bladder Syndrome
Overactive bladder (OAB) is a symptom syndrome characterized by urgency frequency with or without urge urinary incontinence (UUI) that may affect the patients' quality of life.
- Trial name
- NCT01657409
- Testing
- BoNT-A (10 injection), BoNT-A (20 injection), BoNT-A (40 injection)
- Where
- Taiwan
- Volunteers
- 90 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Overactive Bladder, Neurogenic Detrusor Overactivity
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)
The purpose of the study is to evaluate the pharmacokinetics (PK) of mirabegron oral suspension after single dose administration in children with neurogenic detrusor overactivity (NDO) or overactive bladder (OAB).
- Trial name
- NCT02526979
- Testing
- mirabegron
- Where
- 3 sites in Denmark, Poland
- Volunteers
- 9 people
- Sponsor
- Astellas Pharma Europe B.V.
Urinary Incontinence
Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium
This study will evaluate the impact of BOTOX® treatment on anticholinergic drug use in patients with urinary incontinence from Neurogenic Detrusor Overactivity (NDO) due to spinal injury or Multiple Sclerosis (MS) who are…
- Trial name
- NCT02072928
- Testing
- botulinum toxin Type A
- Where
- 6 sites in Belgium
- Volunteers
- 55 people
- Sponsor
- Allergan
Urinary Incontinence, Multiple Sclerosis
Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
This study will evaluate the safety and efficacy of OnabotulinumtoxinA (BOTOX®) for the treatment of urinary incontinence due to NDO in non-catheterizing patients with MS.
- Conditions
- Urinary Incontinence, Multiple Sclerosis, Neurogenic Bladder
- Trial name
- NCT01600716
- Testing
- OnabotulinumtoxinA
- Where
- 10 sites in United States, Belgium and 6 more
- Volunteers
- 144 people
- Sponsor
- Allergan
Urinary Bladder, Overactive
Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity
This study will evaluate the efficacy and safety of GSK1358820 in Japanese patients with neurogenic detrusor overactivity (NDO) with urinary incontinence, whose symptoms have not been adequately managed with medications for…
- Trial name
- NCT02849418
- Testing
- GSK1358820
- Where
- 9 sites in Japan
- Volunteers
- 21 people
- Sponsor
- GlaxoSmithKline
Detrusor Overactivity
Ultrasonographic Bladder Wall Thickness and Different Forms of Detrusor Overactivity
In the last decade, several authors proposed ultrasound measurement of Bladder wall thickness (BWT) for the screening of the voiding dysfunction and of the detrusor overactivity (DO).
- Trial name
- NCT01003457
- Testing
- ultrasonography
- Where
- Italy
- Volunteers
- healthy volunteers welcome
- Sponsor
- Università degli Studi dell'Insubria
Neurogenic Detrusor Overactivity
Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury
Study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of Rec 0/0438 in subjects with neurogenic detrusor overactivity due to spinal cord injury
- Trial name
- NCT03482037
- Testing
- Rec 0/0438 1 mg or Rec 0/0438 2 mg
- Where
- 9 sites in Czechia, France and 2 more
- Volunteers
- 42 people
- Sponsor
- RECORDATI GROUP
Spinal Cord Injury, Acute
Transcutaneous Tibial Nerve Stimulation in Acute Spinal Cord Injury
Most patients with spinal cord injury (SCI) develop neurogenic lower urinary tract dysfunction (NLUTD), one of the most devastating sequelae of SCI which ultimately can lead to renal failure.
- Trial name
- TASCI (NCT03965299)
- Testing
- VERUM TTNS
- Where
- 4 sites in Switzerland
- Volunteers
- 114 people
- Sponsor
- University of Zurich
Overactive Bladder (OAB), Detrusor Overactivity
Bladder Training With or Without Biofeedback-Assisted Pelvic Floor Muscle Training for Women With Wet Overactive Bladder
Overactive bladder causes a sudden and difficult-to-control need to urinate and may be accompanied by urine leakage. Bladder training is commonly used as a first-line treatment.
- Conditions
- Overactive Bladder (OAB), Detrusor Overactivity, Urgency Urinary Incontinence
- Trial name
- NCT07728747
- Testing
- Bladder Training, EMG Biofeedback-Assisted Pelvic Floor Muscle Training
- Where
- Turkey (Türkiye)
- Volunteers
- 64 people
- Sponsor
- Gaziantep Islam Science and Technology University